期刊文献+

迭代二步法估算阿米卡星的群体药动学参数 被引量:2

Estimating population pharmacokinetic parameters of amikacin by iterative two stage method
下载PDF
导出
摘要 目的 :用迭代二步法估算阿米卡星的群体药动学参数。方法 :收集 5 8例呼吸系统感染病人静脉滴注阿米卡星的临床血药浓度监测数据 ,用荧光偏振免疫法测定阿米卡星血药浓度 ,用迭代二步法估算阿米卡星的群体及个体药动学参数。比较性别、年龄、体重、肌酐清除率等因素对药动学参数的影响。结果 :性别对药动学参数无影响 ,CL与CLcr呈正相关 ,Vd 与体重呈正相关。结论 :迭代二步法能较好地估算出阿米卡星的群体及个体药动学参数 。 OBJECTIVE To estimate population pharmacokinetic parameters of amikacin by iterative two stage method. METHODS Clinical data were collected from 58 patients with respiratory tract infection receiving amikacin by intravenous infusion. Concentrations of amikacin in serum were determined by fluorescence polarization immunoassay. Population pharmacokinetic parameters were estimated by iterative two stage method. The influence of sex, age, body weight and creatinine clearance on pharmacokinetic parameters was investigated. RESULTS It was shown that the pharmacokinetic parameters of amikacin were influenced by creatinine clearance and body weight. CONCLUSIONS Iterative two stage method is suitable for estimation of population pharmacokinetic parameters,optimizing individualizing dosage regimens and forecasting plasma concentration.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2001年第12期717-719,共3页 Chinese Journal of Hospital Pharmacy
关键词 阿米卡星 群体药动学 迭代二步法 amikacin population pharmacokinetics iterative two stage method
  • 相关文献

参考文献7

二级参考文献15

  • 1李珍,陈刚.群体药动学研究中非线性混合效应模型法的评价和应用[J].国外医学(药学分册),1993,20(4):195-199. 被引量:8
  • 2夏东亚,刘宝庆,隋因.应用Bayesian反馈法预测阿替洛尔药物动力学参数及血药浓度[J].中国医院药学杂志,1996,16(8):339-341. 被引量:8
  • 3陈刚,治疗药物监测.理论与实践,1988年,172页
  • 4杨友春,中国药理学报,1983年,4卷,4期,217页
  • 5曾衍霖.临床药代动力学中群体及个体参数的估算[J]中国临床药理学杂志,1986(01).
  • 6J. E. Bennett,J. C. Wakefield. A comparison of a bayesian population method with two methods as implemented in commercially available software[J] 1996,Journal of Pharmacokinetics and Biopharmaceutics(4):403~432
  • 7Pascal Girard,Lewis B. Sheiner,Helen Kastrissios,Terrence F. Blaschke. Do we need full compliance data for population pharmacokinetic analysis?[J] 1996,Journal of Pharmacokinetics and Biopharmaceutics(3):265~282
  • 8René Bruno,Nicole Vivier,Jean Claude Vergniol,Susan L. Phillips,Guy Montay,Lewis B. Sheiner. A population pharmacokinetic model for docetaxel (Taxotere?): Model building and validation[J] 1996,Journal of Pharmacokinetics and Biopharmaceutics(2):153~172
  • 9E. Niclas Jonsson,Janet R. Wade,Mats O. Karlsson. Comparison of some practical sampling strategies for population pharmacokinetic studies[J] 1996,Journal of Pharmacokinetics and Biopharmaceutics(2):245~263
  • 10Nicola G. Best,Keith K. C. Tan,Wally R. Gilks,David J. Spiegelhalter. Estimation of population pharmacokinetics using the Gibbs sampler[J] 1995,Journal of Pharmacokinetics and Biopharmaceutics(4):407~435

共引文献30

同被引文献16

  • 1崔俊昌,刘又宁,王睿,梁蓓蓓,裴斐,郑专杰.4种氟喹诺酮类药物对金黄色葡萄球菌的防耐药变异浓度[J].中华医学杂志,2004,84(22):1863-1866. 被引量:34
  • 2孙小平,黄文祥.单剂注射用盐酸多西环素的药动学研究[J].中国抗生素杂志,2006,31(10):624-626. 被引量:6
  • 3苏银法,白学敏.SPSS估算一级并行米氏消除药物药动学参数的方法[J].医药导报,2007,26(1):78-80. 被引量:2
  • 4李朝霞,刘又宁,王睿,童卫杭,程仕虎.左氧氟沙星联合万古霉素缩小金黄色葡萄球菌耐药突变选择窗的初步研究[J].中国临床药理学与治疗学,2007,12(8):911-914. 被引量:32
  • 5Dong Yu-zhi, Zhao Xi-lin, Domagala J, et al. Effect of fluoro- quilonone concentration on selection of resistant mutants of Mycobactedum boris BCG and Staphylococcus aureus [J]. Antimicro Agents Chemother, 1999, 43: 1756-1758.
  • 6Zhao Xi-lin, Drlica K. Restricting the selection of antibiotic- resistant mutants: a general strategy derived from fluoroquinolone studies [J]. Clin Infect Dis, 2001, 33(Supp13): 147-156.
  • 7Drlica K, Zhao Xi-lin. Mutant selection window hypothesis updated [J]. Clin Infect Dis, 2007, 44(5): 681-688.
  • 8Clinical and Laboratory Standards Institute. Performance stan- dards for antimicrobial susceptibility testing; Twentieth informa- tional supplement. CLSI documents M100-S20 [M]. USA: Clin- ical and Laboratory Standards Institute, 2010, 30(1): 121-136.
  • 9Zhanel G G, Mayer M, Laing N, et al. Mutant prevention con- centrations of levofloxacin, ciprofloxacin alone and in combina- tion with azithromycin, eeftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa [J]. Antimicrob Agents Chemother, 2006, 50(6): 2228-2230.
  • 10Firsov A A, Vostrov S N, Lubenko I Y, et al. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination [J]. Antimicrob Agents, 2004, 23: 451-456.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部